Jubiglim MV 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, reducing postprandial hyperglycemia. This synergistic formulation targets multiple pathophysiological defects in type 2 diabetes, providing comprehensive glycemic control. Jubiglim MV 2 Tablet SR is typically prescribed when monotherapy or dual therapy is insufficient to achieve desired glycemic targets. It is essential to administer the tablet as directed by a healthcare professional, usually with meals to minimize gastrointestinal side effects. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Caution is advised in patients with renal or hepatic impairment, and periodic monitoring of blood glucose and renal function is recommended. This combination therapy should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular medical follow-up.